Logo Lucerna-Chem
+41 41 420 9636

Regulatory Status

Article Status


JAK2-IN-7


Catalog Number Pack Size List Price* Promo Price* Quantity
HY-131906-5MG 5 mg 537,00 456,50 Add
HY-131906-10MMO 10 mM * 1 mL 544,00 462,40 Add
HY-131906-10MG 10 mg 881,00 748,90 Add
HY-131906-25MG 25 mg 1'814,00 1'541,90 Add
HY-131906-50MG 50 mg 2'803,00 2'382,60 Add
HY-131906-100MG 100 mg 4'177,00 3'550,50 Add

* CHF, excl. 7.7% VAT and shipping costs


Product Description

JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities.

Category Inhibitor
Supplier MedChem Express
Application Cancer-Kinase/protease
Regulatory Status RUO
Format Solubility: DMSO : 250 mg/mL (543.96 mM; Need ultrasonic)
Grade Clinical information: No Development Reported
Purity 99.42%
Molecular Formula C26H33N7O
Molecular Weight 459.59
Storage Conditions Powder -20°C 3 years, 4°C 2 years; In solvent -80°C 6 months, -20°C 1 month
Product Line Research
Tech. Data Sheet View datasheet
Link To Supplier http://www.medchemexpress.com
Material Safety Data Sheet Download PDF
Call us

Customer Support
T +41 41 420 96 36
F +41 41 420 96 56
info@lucerna-chem.ch

Business Hours
From Monday through Friday
08:00 – 12:00
13:00 – 17:00

Ask us

Technical Support
tech@lucerna-chem.ch

Business Development
business.dev@lucerna-chem.ch

Postal address
Lucerna-Chem AG
Abendweg 18
CH-6006 Luzern

Newsletter













If you have already subscribed to our newsletter and would like to update your details or cancel it, please click here.


© Copyright 2021 Lucerna-Chem AG, Switzerland